Combating Glioblastoma by Codelivering the Small-Molecule Inhibitor of STAT3 and STAT3siRNA with α5β1 Integrin...

Area of Science:

• Neuro-oncology
• Nanomedicine
• Drug Delivery

Background:

• Glioblastoma multiforme (GBM) is a highly aggressive brain tumor with poor prognosis.
• The blood-brain barrier (BBB) presents a significant obstacle for effective drug delivery to brain tumors.
• Targeting overexpressed receptors on brain capillary endothelial cells (BCECs) offers a strategy for drug delivery.

Purpose of the Study:

• To evaluate the therapeutic potential of RGDK-lipopeptide liposomes co-delivering WP1066 and STAT3 siRNA for glioblastoma treatment.
• To assess the brain tumor targeting and accumulation of α5β1 integrin receptor-selective liposomes.
• To determine the efficacy of this combined therapy in an orthotopic mouse glioblastoma model.

Main Methods:

• Development of nanometric (100-150 nm) RGDK-lipopeptide liposomes targeting the α5β1 integrin receptor.
• Internalization studies of labeled liposomes in GL261 glioblastoma cells.
• In vivo evaluation of brain tumor targeting and accumulation of NIR-dye-labeled liposomes in mice.
• Assessment of tumor growth inhibition following intravenous administration of WP1066 and STAT3 siRNA encapsulated in RGDK-lipopeptide liposomes.

Main Results:

• RGDK-lipopeptide liposomes were successfully internalized via α5β1 integrin receptors in GL261 cells.
• Intravenously administered liposomes showed preferential accumulation in mouse brain tumor tissue.
• Co-delivery of WP1066 and STAT3 siRNA via RGDK-lipopeptide liposomes resulted in significant inhibition (>350%) of orthotopic glioblastoma growth.

Conclusions:

• RGDK-lipopeptide liposomes effectively target brain tumors and facilitate the co-delivery of therapeutic agents.
• This targeted nanomedicine approach demonstrates significant therapeutic efficacy against glioblastoma in a preclinical model.
• The strategy holds promise for future development of advanced therapies for glioblastoma multiforme.